Feasibility of Identifying Factors Related to Alzheimer’s Disease and Related Dementia in Real-World Data

Author:

Chen Aokun,Li Qian,Huang Yu,Li Yongqiu,Chuang Yu-neng,Hu Xia,Guo Serena,Wu Yonghui,Guo Yi,Bian JiangORCID

Abstract

ABSTRACTA comprehensive view of factors associated with AD/ADRD will significantly aid in studies to develop new treatments for AD/ADRD and identify high-risk populations and patients for prevention efforts. In our study, we summarized the risk factors for AD/ADRD by reviewing existing meta-analyses and review articles on risk and preventive factors for AD/ADRD. In total, we extracted 477 risk factors in 10 categories from 537 studies. We constructed an interactive knowledge map to disseminate our study results. Most of the risk factors are accessible from structured Electronic Health Records (EHRs), and clinical narratives show promise as information sources. However, evaluating genomic risk factors using RWD remains a challenge, as genetic testing for AD/ADRD is still not a common practice and is poorly documented in both structured and unstructured EHRs. Considering the constantly evolving research on AD/ADRD risk factors, literature mining via NLP methods offers a solution to automatically update our knowledge map.HIGHLIGHTSWe summarized the risk factors for AD/ADRD by reviewing existing meta-analyses and review articles on risk and preventive factors for AD /ADRD.Drawing from this literature review and identified AD/ADRD factors, we explored the accessibility of these risk and preventive factors in both structured and unstructured EHR data.We constructed an interactive knowledge map that can be used to aid in the design of future AD/ADRD studies that aim to leverage large collections of RWD to generate RWE.

Publisher

Cold Spring Harbor Laboratory

Reference275 articles.

1. (2023) 2023 Alzheimer’s disease facts and figures. Alzheimers Dement.

2. Review: Therapy for Alzheimer's disease: how effective are current treatments?

3. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease;J Prev Alzheimers Dis,2022

4. Lecanemab for Alzheimer's disease: tempering hype and hope

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3